findmyKOL
Clinical trialNCT07318389Not, yet, recruitingEarly phase 1Interventional

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

SponsorM.D. Anderson Cancer CenterEnrollment100Dynamic Tumor ResistanceMetastatic Colorectal Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Adagrasib →Bevacizumab →Cetuximab →Encorafenib →FOLFIRI Regimen →Folfox →Panitumumab →Sotorasib →Trastuzumab →Trifluridine →Tucatinib →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
10 Jun 2026
Primary completion
14 Nov 2027
Completion
14 Nov 2029
Last update posted
11 Jun 2026
Registered enrollment
100
Registry id
NCT07318389
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.